Home / Provider Reviews / LillyDirect Review
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.
Released: ·Last reviewed: ·Prices verified October 15, 2026·Methodology v4.1

LillyDirect review (2026): self-pay prices, rules, pros and cons

Direct answer · October 15, 2026

As of October 15, 2026, LillyDirect’s self-pay prices are Zepbound $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5–15 mg when each refill is bought within 45 days (otherwise $499 at 7.5 mg and $699 at 10–15 mg), and Foundayo from $149, per LillyDirect pages archived in late September.

lilly.com blocked our direct read on October 15, so these are reported from archived copies dated September 25–30, 2026.

Verdict

LillyDirect is Eli Lilly selling its own medicines for self-pay. You get the FDA-approved product at the manufacturer’s price, with no telehealth membership on top, but you must bring a prescription. Zepbound is $299 at 2.5 mg and $399 at 5 mg. At 7.5 mg and above it is $449, but only if you buy each refill within 45 days; miss that and it is $499 at 7.5 mg and $699 at 10–15 mg.

Foundayo, Lilly’s oral GLP-1, is $149 at 0.8 mg, and $149 at 2.5 mg and $199 at 5.5 mg under a temporary reduction that runs through December 31, 2026. It is $299 at 9 mg, and $299 at 14.5 and 17.2 mg with 45-day refills (regularly $349). On our October read, Foundayo at 0.8 mg and the Wegovy pill at 1.5 mg share the lowest self-pay price for an FDA-approved GLP-1 weight-loss medicine, $149 a month.

Two cautions. These figures come from archived pages because lilly.com blocked our read, and the Foundayo reductions expire at year end. And brand prices rise with dose, so budget at your maintenance dose, not the starting one. This site has not yet scored LillyDirect on methodology v4.1 (v4.1 score pending).

Snapshot

LillyDirect snapshot · each field with its source and read date · status as of October 15, 2026
FieldWhat the provider’s page saysSource · read dateStatus
Zepbound 2.5 mg · 5 mg$299 · $399 a monthLillyDirect, archived Sept 30, 2026Reported — pending verification
Zepbound 7.5–15 mg$449 with each refill inside 45 daysLillyDirect, archived Sept 30, 2026Reported — pending verification
Zepbound, late refill$499 (7.5 mg), $699 (10–15 mg)LillyDirect, archived Sept 30, 2026Reported — pending verification
Foundayo 0.8 · 2.5 · 5.5 mg$149 · $149 · $199 (reductions through Dec 31, 2026)LillyDirect, archived Sept 25, 2026Reported — pending verification
Foundayo 9 · 14.5 · 17.2 mg$299 (45-day refills at the top doses; regularly $349)LillyDirect, archived Sept 25, 2026Reported — pending verification
MembershipNoneLillyDirect, archived Sept 2026Reported — pending verification
PrescriptionRequiredLillyDirect, archived Sept 2026Reported — pending verification
Medicare Part D$50 copay under the GLP-1 Bridge, Jul 1, 2026–Dec 31, 2027CMSVerified

Pricing, October 15, 2026

A year of Zepbound at a steady 7.5–15 mg dose costs $5,388 with on-time refills ($449 × 12). The same year with late refills at 10–15 mg would be $8,388. Prices below are per monthly fill.

LillyDirect self-pay prices · archived LillyDirect pages dated September 25–30, 2026 · lilly.com blocked our October 15, 2026 read
Medicine and dosePer monthConditionSource
Zepbound 2.5 mg$299—Lilly, archived Sept 30
Zepbound 5 mg$399—Lilly, archived Sept 30
Zepbound 7.5–15 mg$449Each refill within 45 daysLilly, archived Sept 30
Zepbound 7.5 mg / 10–15 mg, late refill$499 / $699Refill after 45 daysLilly, archived Sept 30
Foundayo 0.8 mg$149—LillyDirect, archived Sept 25
Foundayo 2.5 mg / 5.5 mg$149 / $199Reduced through Dec 31, 2026LillyDirect, archived Sept 25
Foundayo 9 mg / 14.5–17.2 mg$299 / $299Top doses: 45-day refills (regular $349)LillyDirect, archived Sept 25

What changed since our July 2026 review

The July 2026 figures below are kept only so you can see what moved. None of them is a current price.

LillyDirect · July 2026 capture (superseded) vs October 15, 2026 read
ItemJuly 2026 (superseded)October 15, 2026
Zepbound$299 / $399 / $449Unchanged
FoundayoFrom $149, rising to $199, $299 and $349$149 / $149 / $199 / $299 / $299 (reductions through Dec 31)
Who LillyDirect suitsLillyDirect is a pharmacy channel, not a clinic: you need a valid prescription. Eligible Medicare Part D enrollees can pay a $50 copay under the GLP-1 Bridge from July 1, 2026 to December 31, 2027 (CMS), and Lilly’s September page said a commercial savings card can bring a fill to “as little as $25” for people whose insurance covers Zepbound. Check your coverage first.

Pros and cons

Pros

  • FDA-approved medicine at the manufacturer’s price
  • No membership or telehealth markup
  • Foundayo at $149 ties for the lowest FDA-approved self-pay price we track
  • Medicare Part D bridge at $50 for eligible enrollees

Cons

  • Prescription required; no clinical care included
  • Zepbound jumps to $499–$699 if a refill is late
  • Foundayo reductions end December 31, 2026
  • lilly.com blocked our direct read

Evidence ledger

LillyDirect evidence ledger · claim, source, read date, status
ClaimSourceReadStatus
Zepbound $299 / $399 / $449; late-refill $499 / $699LillyDirect page archived 2026-09-30October 15, 2026Reported — pending verification
Foundayo price ladderLillyDirect pages archived 2026-09-25October 15, 2026Reported — pending verification
Medicare GLP-1 Bridge $50CMSOctober 15, 2026Verified

Limits. We read public pages and date each read. We have not audited pharmacy licences or measured patient outcomes, and we publish no user ratings. Confirm any price at checkout.

Alternatives to compare

Every program we track, with read dates, is in the GLP-1 pricing database.

Before you pay

  1. Find the ongoing price. Words like “first month”, “from”, “as low as” or “sale” mean the number beside them is not what month two costs.
  2. Add any membership and ask, in writing, the price at your maintenance dose.
  3. Ask what happens if you stop early on any plan longer than one month.
  4. Ask which pharmacy fills the prescription and whether it is a 503A or 503B facility, then check its licence with the state board of pharmacy.

Frequently asked questions

How much is Zepbound on LillyDirect in October 2026?

Per LillyDirect pages archived September 30, 2026 (lilly.com blocked our direct read on October 15), Zepbound costs $299 at 2.5 mg, $399 at 5 mg and $449 at 7.5 to 15 mg if each refill is bought within 45 days. Otherwise it is $499 at 7.5 mg and $699 at 10 to 15 mg.

How much is Foundayo on LillyDirect?

Per LillyDirect pages archived September 25, 2026, Foundayo is $149 at 0.8 mg, $149 at 2.5 mg and $199 at 5.5 mg under reductions that run through December 31, 2026, then $299 at 9 mg and $299 at 14.5 and 17.2 mg with 45-day refills (regularly $349).

What is the 45-day refill rule?

Lilly’s self-pay offer keeps the $449 Zepbound price at 7.5 mg and above only if you complete each refill purchase within 45 days. If you refill later, the price rises to $499 at 7.5 mg and $699 at 10 to 15 mg.

What is the cheapest FDA-approved GLP-1 without insurance?

As of October 15, 2026, the lowest self-pay price for an FDA-approved GLP-1 weight-loss medicine is $149 a month: the Wegovy pill at 1.5 mg through NovoCare, and Foundayo at 0.8 mg through LillyDirect, where 2.5 mg is also $149 under a reduction that runs through December 31, 2026. Prices rise with dose.

Sources

  1. Lilly — Zepbound coverage and savings (LillyDirect self-pay) (archived copy dated September 30, 2026; lilly.com blocked our direct read on October 15, 2026)
  2. LillyDirect — Foundayo self-pay pricing (archived copy dated September 25, 2026; lilly.com blocked our direct read on October 15, 2026)
  3. NovoCare Pharmacy — Wegovy self-pay offer (read October 15, 2026)
  4. My Peptide Information — GLP-1 pricing database (October 15, 2026 index: 28 tirzepatide and 22 semaglutide programs)

Researched ByDr. Parmis · Medical Researcher · Western University of Health Sciences

Medically Reviewed ByDr. Jonathan Snipes, MD · Kim Callender, NP (FNP-BC)

Last medically reviewed: · This page is informational and does not constitute medical advice.